Log In
BCIQ
Print this Print this
 

MM-310

  Manage Alerts
Collapse Summary General Information
Company Merrimack Pharmaceuticals Inc.
DescriptionDocetaxel nanoliposome targeting EPH receptor A2 (EPHA2)
Molecular Target EPH receptor A2 (EPHA2)
Mechanism of Action 
Therapeutic ModalityNanotherapy
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today